XTalks

MARCH 7, 2024

Optimizing Sleep During Perimenopause and Beyond Sleep plays a crucial role in overall health, particularly for midlife women transitioning into menopause, a phase marked by perimenopause where hormonal changes can severely disrupt sleep due to symptoms like nocturnal hot flashes.

Hormones 115

Hormones Genetics Genome Genomics 115

Drug Discovery World

MAY 9, 2024

RA: Tell us how OXE103 works? MW: OXE103 (ghrelin) is a 28 amino acid neuro-peptide hormone that crosses the blood brain barrier and is responsible for maintaining brain energy homeostasis and neuroprotection related to neuronal cell preservation, axonal connectivity and decreased inflammation.

Development 72

Development Hormones Drugs Trials 72

XTalks

MAY 27, 2022

This result came from the promising Phase III EMERALD global clinical trial ( NCT03778931 ). Aditya Bardia, principal investigator of the EMERALD clinical trial in their press release statement. The ESR1 gene has also been detected in recurrent local and metastatic cancer cells. which is encoded by the ESR1 gene in humans.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Gene 98

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

HR 98

HR FDA Approval Gene Trials 98

XTalks

FEBRUARY 6, 2023

Erythropoietin is a hormone that is produced by the kidneys and signals the body to make red blood cells. By inhibiting oxygen-sensing prolyl hydroxylase enzymes, Jesduvroq stabilizes hypoxia-inducible factors, and this can lead to the transcription of erythropoietin and other genes that help correct anemia.

FDA Approval 97

FDA Approval Clinical Trials Clinical Trials Trials 97

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. The study was published in the journal PLOS Biology. Related: Can Vitamin D Be Beneficial for COVID-19 Patients? The list also included melatonin.

Research 98

Research Hormones Protein Regulation 98

XTalks

FEBRUARY 3, 2023

Aditya Bardia, MD, MPH, director of Breast Cancer Research at Mass General Cancer Center, associate professor at the Medicine Department at Harvard Medical School and principal investigator for the EMERALD trial, in the same press release statement. In addition, about 40 percent of these cases involve mutations in the ESR1 gene.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

pharmaphorum

JUNE 8, 2022

Zilebesiran (formerly ALN-AGT) is one of a new breed of gene-silencing drugs that are intended to treat common, chronic diseases with infrequent dosing to boost compliance with treatment. In a phase 1 trial, zilebesiran was found to be well-tolerated and improve systolic blood pressure over 12 weeks with a single injection.

Gene Silencing 52

Gene Silencing Drugs Medicine Regulation 52

Drug Discovery World

JANUARY 9, 2024

Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare, Clarivate said: “The fundamentals underpinning the biopharma sector have never been stronger, with new technologies fuelling medical advancements and providing treatment options to patients with previously unmet needs.

Drugs 69

Drugs Gene Editing Antibody Medicine 69

XTalks

JUNE 27, 2022

The BRAF gene regulates cell growth, proliferation and apoptosis. Mutations in this gene can contribute to the growth of different cancer cells, and many patients with cancer carry BRAF mutations. Tafinlar and Mekinist Combination Clinical Trial Results.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Regulation 52

The Pharma Data

APRIL 11, 2023

Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients. For the first time, Bayer will present the design of the clinical trial and the preclinical activity profile of the inhibitor in human epidermal growth factor receptor 2 (HER2) mutant NSCLC.

Research 40

Research Clinical Trials Clinical Trials Trials 40

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. In the 500 patient trial, patients treated with Trodelvy lived for a median of 12.1 months, compared with 6.7 months in patients treated with chemotherapy.

Marketing 74

Marketing Gene Silencing Gene Drugs 74

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid. Evaluate Vantage speculates that given Amvuttra’s potential for ATTR cardiomyopathy, the drug could reach $1.8

FDA Approval 98

FDA Approval Protein Genetics RNA 98

Pharmaceutical Technology

APRIL 24, 2023

Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

MARCH 22, 2021

As a leader in life sciences, diagnostics and applied chemical markets, it is looking to grow its cancer diagnostics pipeline. The antibody accrued promising data in a randomized, placebo-controlled Phase II study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer, and is now being prepared for Phase III trials.

Life Science 110

Life Science Development Marketing Gene Expression 110

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. Strong pipeline with robust late-stage development program and broad potential across indications.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

MARCH 11, 2021

Speaking at the virtual Capital Markets Day on Wednesday, CEO Werner Baumann emphasized Bayer’s long-term growth perspectives: “Bayer is a leading life science company, uniquely positioned at the intersection of health and nutrition – with attractive prospects for growth, earnings and cash flow.”

Sales 52

Sales Gene Therapy Marketing Gene 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52